1. The addition of sofosbuvir to peginterferon-ribavirin was effective at achieving sustained virologic response against HCV genotypes 1, 4, 5 and 6. For HCV genotypes 2 and 3, sofosbuvir and ribavirin was non-inferior to current treatment (peginterferon-ribavirin).
2. Patients treated with sofosbuvir experienced fewer adverse events overall.
Evidence Rating Level: 1 (Excellent)
Study Rundown: There are currently six hepatitis C virus (HCV) genotypes. Since the various genotypes respond differently to treatment, the genotype is one factor that influences the therapy chosen for a chronic HCV carrier. Sofosbuvir is a new HCV polymerase inhibitor that demonstrated high sustained virologic response (SVR) during phase 2 trials. In this study, sofosbuvir was successful at achieving SVR against HCV genotypes 1, 4, 5 and 6 when added to current therapies and was also non-inferior to peginterferon-ribavirin against HCV genotypes 2 and 3. Overall, groups treated with sofosbuvir experienced fewer adverse events. Rapid resistance to treatment has been an issue with past HCV treatments, and sofosbuvir continues to show promise since no viral resistance was detected with deep sequencing assays.
The major limitation to this study was the short follow up time of 12 weeks. Although there was early response to the addition of sofosbuvir, HCV is a chronic infection with various factors influencing relapse. Therefore, relapse rates beyond 12 weeks after sofosbuvir and adverse events from long-term treatment with sofosbuvir will need to be included for future studies.
Click to read the study in NEJM
In-Depth [randomized, open-label, active-control]: This two-part phase 3 trial added sofosbuvir to the current standard of care (peginterferon-ribavirin) for HCV genotypes 1, 4, 5 and 6 (NEUTRINO; n=327) and compared sofosbuvir-ribavirin to peginterferon-ribavirin for HCV genotypes 2 and 3 (FISSION; n=499). The primary endpoint was sustained virologic response at 12 weeks after the end of treatment. This was 90% for patients in the NEUTRINO study and 67% in both groups in FISSION. All common adverse events occurred at a lower rate for the sofosbuvir treated group in FISSION. With the exception of anemia, no hematologic adverse events (such as decreased lymphocyte count, neutrophil count, platelet count) were observed in the sofosbuvir-ribavirin group.
By Jonathan Liu and Mitalee Patil
More from this author: PFO Closure equivalent to medical management in prevention of recurrent stroke, Combo antifungal therapy most effective treatment for cryptococcal meningitis, Rhinovirus, genes may interact to increase risk of childhood asthma, Functional MRI map for physical pain identified, Glutamine and antioxidant supplementation provide no benefit for critically-ill patients
© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.